

Title (en)
ISOLATED MONOCYTE POPULATIONS AND RELATED THERAPEUTIC APPLICATIONS

Title (de)
ISOLIERTE MONOZYTENPOPULATIONEN UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNGEN

Title (fr)
POPULATIONS MONOCYTAIRES ISOLÉES ET APPLICATIONS THÉRAPEUTIQUES ASSOCIÉES

Publication
EP 2398900 A4 20120822 (EN)

Application
EP 10744061 A 20100219

Priority
• US 2010000477 W 20100219
• US 20817309 P 20090220
• US 28324409 P 20091130

Abstract (en)
[origin: WO2010096177A1] The invention provides methods of using isolated monocyte populations to treat subjects suffering from various ocular vascular disease or ocular degenerative disorders. The present invention also provides novel methods for isolating substantially pure monocyte populations. The methods involve extracting a blood sample or a bone marrow sample from a subject, debulking red blood cells from the sample, and then separating remaining red blood cells and other cell types in the sample from monocytes. Instead of using any selection or labeling agents, the red blood cells and other cell types are separated from monocytes based on their size, granularity or density. The isolated monocytes can be further activated in vitro or ex vivo prior to being administered to a subject. Isolated cell populations containing substantially pure CD14+/CD33+ monocytes are also provided in the invention.

IPC 8 full level
C12N 5/0786 (2010.01); **A01N 63/02** (2006.01); **A61K 35/12** (2015.01)

CPC (source: EP KR)
A61K 35/12 (2013.01 - KR); **A61K 39/4614** (2023.05 - EP KR); **A61K 39/4622** (2023.05 - EP KR); **A61K 39/464** (2023.05 - EP KR); **A61P 9/10** (2018.01 - EP); **A61P 27/02** (2018.01 - EP); **A61P 27/06** (2018.01 - EP); **C12N 5/0645** (2013.01 - EP KR); **A61K 2035/124** (2013.01 - EP); **A61K 2239/31** (2023.05 - EP KR); **C12N 2501/051** (2013.01 - EP); **C12N 2501/052** (2013.01 - EP); **C12N 2501/21** (2013.01 - EP); **G01N 15/042** (2013.01 - EP); **G01N 15/149** (2024.01 - EP); **G01N 2015/1497** (2013.01 - EP)

Citation (search report)
• [XY] WO 2008001380 A2 20080103 - YEDA RES & DEV [IL], et al
• [Y] WO 2006031467 A2 20060323 - SCRIPPS RESEARCH INST [US], et al
• [Y] HAZIOT A ET AL: "SOLUBLE CD14 INHIBITS THE ACTIVATION OF MONOCYTES INDUCED BY LPS", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT, A.R. LISS, NEW YORK, NY, US, 21 February 1992 (1992-02-21), pages 163, XP000775642, ISSN: 0733-1959
• [Y] SUMEGI ET AL: "Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 117, no. 3, 1 December 2005 (2005-12-01), pages 271 - 279, XP005226349, ISSN: 1521-6616, DOI: 10.1016/J.CLIM.2005.09.002
• [A] AGUILAR EDITH ET AL: "OCULAR MODELS OF ANGIOGENESIS", METHODS IN ENZYMOLOGY ELSEVIER ACADEMIC PRESS INC, 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SERIES : METHODS IN ENZYMOLOGY (ISSN 0076-6879(PRINT)), 2008, pages 115 - 158, XP009160775
• See also references of WO 2010096177A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DOCDB simple family (publication)
WO 2010096177 A1 20100826; AU 2010216374 A1 20110818; BR PI1008392 A2 20150825; CA 2752679 A1 20100826; CN 102317446 A 20120111; EA 201190109 A1 20120730; EP 2398900 A1 20111228; EP 2398900 A4 20120822; JP 2012518407 A 20120816; KR 20110123778 A 20111115; MX 2011008826 A 20111102; ZA 201105869 B 20121031

DOCDB simple family (application)
US 2010000477 W 20100219; AU 2010216374 A 20100219; BR PI1008392 A 20100219; CA 2752679 A 20100219; CN 201080007973 A 20100219; EA 201190109 A 20100219; EP 10744061 A 20100219; JP 2011551065 A 20100219; KR 20117021989 A 20100219; MX 2011008826 A 20100219; ZA 201105869 A 20110811